Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;26(1):43-51.
doi: 10.1097/IGC.0000000000000586.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers

György Sölétormos  1 , Michael J Duffy, Suher Othman Abu Hassan, René H M Verheijen, Bengt Tholander, Robert C Bast Jr, Katja N Gaarenstroom, Catharine M Sturgeon, Johannes M Bonfrer, Per Hyltoft Petersen, Hugo Troonen, Gian CarloTorre, Jan Kanty Kulpa, Malgorzata K Tuxen, Raphael Molina
Affiliations

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers

György Sölétormos et al. Int J Gynecol Cancer. 2016 Jan.

Abstract

Objective: To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial ovarian cancer.

Methods: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation.

Results: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery.

Conclusions: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Nonmalignant conditions causing elevated CA125 concentrations.
FIGURE 2
FIGURE 2
Frequency of elevated CA125 concentrations in different malignancies.
See this image and copyright information in PMC

References

    1. Bast RC, Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309: 883– 887. - PubMed
    1. Donach M, Yu Y, Artioli G, et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol. 2010; 31: 209– 215. - PubMed
    1. Jacobs I, Bast RC., Jr The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4: 1– 12. - PubMed
    1. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005; 15: 679– 691. - PubMed
    1. Liu J, Matulonis UA. Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep. 2011; 13: 450– 458. - PubMed

MeSH terms